A Phase 1,Multi-center, Randomized, Open, Single-dose Escalation Design to Evaluate the Safety, Tolerability and Pharmacodynamics of STSP-0601 for Injection in Patients With Inhibitory Hemophilia
Latest Information Update: 26 Sep 2024
At a glance
- Drugs STSP-0601 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Staidson Beijing BioPharmaceuticals
Most Recent Events
- 14 Feb 2023 Status changed from recruiting to completed.
- 14 Feb 2023 Results assessing the efficacy and safety of STSP-0601 in preclinical and clinical studies published in the Journal of Thrombosis and Haemostasis
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition